Experimental Article

Effect of a short term pulmonary rehabilitation programme on exercise capacity, pulmonary function and health related quality of life in patients with COPD

Bangi A. Naseer, M.P.Tha, Abdullah M. Al-Shenqiti, PhDa, AbdulRahman H. Ali, PhDb,*, Talal M. Al-Jeraisi, MSc Otorhinolaryngologyb, Garg G. Gunjan, M.P.Thc and Mohammed F. Awaidallah, MDa

a Faculty of Medical Rehabilitation Sciences, Taibah University, KSA
b Head & Neck Surgery Department, Faculty of Medicine, Taibah University, KSA
c Jamia Hamdard University, New Delhi, India

Received 13 February 2017; revised 20 July 2017; accepted 27 July 2017; Available online 23 August 2017

Abstract

Objectives: Patients with chronic obstructive pulmonary disease (COPD) have been shown to benefit from pulmonary rehabilitation programmes. The purpose of this study was to ascertain the effects of a short-term pulmonary rehabilitation programme (PRP) on exercise capacity, pulmonary function and quality of life in patients with COPD.

Methods: A pre-test and post-test experimental design was conducted on patients from the outpatient physical therapy department. Thirty stable COPD patients with mild to severe airflow obstruction, (mean age 54.1 ± 5.22, FEV1, between 0.80 and 0.30 predicted; FEV1/FVC < 0.70) were recruited for a 6-week comprehensive pulmonary rehabilitation programme (PRP) that included education and exercise training. Exclusion criteria included the following: cardiovascular conditions likely to be aggravated by exercise, locomotor impairment, haemoptysis, cognitive impairment, severe pulmonary hypertension, and metastatic cancer. The patients were randomly divided into experimental and control groups.

* Corresponding address: Examination Control, College of Medical Rehabilitation, PO Box 3893, Almadinah Almunawwarah, KSA.
E-mail: abrahaman@hotmail.com (A.H. Ali)
Peer review under responsibility of Taibah University.
Introduction

COPD is the most common cause of mortality and disability associated with lung diseases. The World Health Organization, in a more recent projection, predicts COPD to rise from its recent ranking as the fifth most common cause of mortality to the fourth most common by 2030, which would place it behind only ischaemic cerebrovascular disease, HIV/AIDS and heart disease.1 Even more importantly, COPD is a rising cause of chronic disability and is predicted to become the fifth most common cause of chronic disability worldwide by 2020.2 In India, the population prevalence in a large multi-centric study related to COPD was 4.1% of 35 and 295 subjects with a male: female ratio of 1.56:1.3 The widespread smoking habit and the use of fuel have both led to the high prevalence of COPD.

The loss of physical capacity associated with the adverse psychological effects of the disorder greatly impact the disease. Medicines have a limited role in improving the physical capacity of these patients.4 The evolving endorsed standard of care for patients with chronic lung disease is pulmonary rehabilitation, based on the developing body of scientific evidence.5 We perceive that there are many scientific developments where the systemic effects of chronic respiratory disease and the variations that occurred were through the process of pulmonary rehabilitation and Exercise intolerance, predominantly with disease progression, is a hallmark of COPD.6,7 Abnormalities in cardiac function, ventilatory mechanics, respiratory mechanics, and alveolar gas exchange are present to varying degrees in patients with COPD.8 The inactivity initiates a concatenation of events where breathlessness increases at even lower physical demands and is associated with progressive deconditioning.

To have an effective rehabilitation programme, exercise reconditioning is the foundation; a physical activity programme ignites the cardiovascular and skeletal muscles so that functional changes in the skeletal system are brought about that reverse the detrimental effects of deconditioning and further systemic manifestations of COPD that affect skeletal muscles.9 The management of patients with chronic respiratory disease has developed remarkably, and this extensive mediation has established improvements in exercise performance, reduction in dyspnoea, and recovery of health-related quality of life with evidence-based support for pulmonary rehabilitation.10

There is an association between COPD and upper airway symptoms, especially sinonasal symptoms. It is very important to consider the relationship between lower and upper airway inflammation and bacteria. Impairment in quality of life because of COPD could be the primary reason for upper airway symptoms; the nasal and sinus symptoms are considered the most important factor causing impairment to quality of life. Epidemiological studies suggest that more than 1/3 of patients with sinusitis have COPD, and 75% of patients with COPD have associated nasal symptoms. The similarity of the inflammatory response to the lower and upper airways stems from similar exposure to allergens and irritant; in some patients, sinusitis or rhinitis and COPD coexist together, which could be due to the mechanism of nasal bronchial reflex. In this study, we exclude all patients with COPD that have upper airway symptoms.

With the current state of information, an outpatient rehabilitation programme with a multidisciplinary team offers rehabilitation with comparably safe advancements in clinically applicable endpoints, such as health-related quality of life functionality and use of health care assets at an agreeable cost.11 Since there are no established protocols for pulmonary rehabilitation programmes so far for these patients, the purpose of the present study is to develop a short, comprehensive, and cost-effective pulmonary rehabilitation programme that is more easily accessible for patients with COPD who have a restricted exercise capacity and who otherwise may be required to deal with the high cost of a multidisciplinary programme at a large hospital. For this purpose, an exercise protocol is developed that includes upper limb exercises, thoracic mobility exercises and lower limb endurance exercises totalling 1.5 h in duration as an OPD programme, 3 days per week for 3 consecutive weeks. Later, a home exercise programme is given for another 3 weeks as a maintenance programme. Outcome measures include exercise capacity, HRQOL, pulmonary function as measured by 6MWD, St. George’s Respiratory Questionnaire, and spirometry performed at baseline, at the end of the 3rd week and at the end of the 6th week. The data collected is compared to the improvement in the chosen variables. The significance of the study lies in improving the physical and psychological status of the patients, improving their ability to interact with their atmosphere, improving their knowledge of the disease, and refining their self-management strategies. If the study shows significant results, this protocol can be implemented with COPD patients as part of their disease management.

Materials and Methods

Patients were recruited from Pulmonology OPD. Thirty patients were included in the study, who displayed the following characteristics: stable COPD and mild to severe airflow obstruction; FEV1 > 30% predicted, FEV1/FVC < 70%; optimized medical therapy; dyspnoeic in daily...
activities; had never attended any exercise programme; had no associated comorbid disease. Exclusion criteria were cardiovascular conditions that were likely to be aggravated by exercise, locomotor impairment, haemoptysis, cognitive impairment, severe pulmonary hypertension, and metastatic cancer.

The patients included were randomly divided into experimental and control groups. The programme was conducted by a physiotherapist, and patients in the experimental group attended 3 times a week for the first 3 weeks of the pulmonary rehabilitation programme. For the next 3 weeks, they were instructed in a home exercise programme. The patients in the control group were briefed on a home exercise programme for 6 weeks. The pulmonary rehabilitation programme consisted of four repetitions of upper limb exercises (shoulder girdle circling, arm circling) and thoracic mobility exercises each, as well as a lower limb endurance-training programme using a cycle ergometer and treadmill. Patient education and counselling were given to every patient in both groups. Exercise capacity, pulmonary function and health-related quality of life were assessed by the six-minute walk test, FEV1, FVC, FEV1/FVC, SGRQ scores respectively at baseline, at the end of the 3rd week and at the end of the 6th week.

The six-minute walk test was used for measuring exercise capacity. It was performed in a 30-metre-long, unobstructed hospital corridor. This test was done according to ATS guidelines. Patients were asked to walk as far as they could in 6 min. They could detect their own pace or even stop if they had to, and they were told that at the end of the 6 min they should feel as though they could not have walked any further. Before starting the test, blood pressure, heart rate, oxygen saturation, and RPE were measured. During the test, heart rate and oxygen saturation were measured with a pulse oximeter. After the completion of 6 min, all variables were measured again; distance walked by the patient was noted in metres. The Borg scale was used for the RPE score.

Pulmonary function was assessed by FEV1. It was measured by a computerized pulmonary spirometry machine (ZAN300 Me BGE rate GmbH). Values were expressed in percentage predicted. HRQOL was compared using the St. George’s Respiratory Questionnaire (SGRQ). Two versions of the questionnaire – Hindi and English – were used for the patients based on their education type. Scores ranged from 0 to 100, with a score of zero indicating no impairment. The total score was used for the analysis.

Data analysis

Data are represented as descriptive statistics. Statistical analysis was done by SPSS 16. Repeated measures ANOVA were used to assess the changes in outcome measures after the rehabilitation programme from baseline. The differences between the two groups were analysed by independent samples t test.

Results

Thirty-four patients were recruited for the study, of which 4 patients did not complete the programme. Fifteen patients were included in both the experimental and control group.

| Table 1: Subject characteristics. |
|----------------------------------|
|                                | Group A | Group B |
|                                | *Mean ± SD | *Mean ± SD |
| Sample (n)                     | 15      | 15      |
| Age (years)                    | 56.53 ± 5.24* | 51.67 ± 4.03* |
| Height (cms)                   | 164.4 ± 6.53* | 168.38 ± 4.22* |
| Weight (kg)                    | 65.2 ± 10.26* | 67.63 ± 6.92* |
| FEV (%predicted)               | 47.27 ± 11.07* | 45.87 ± 8.72* |
| FVC (%predicted)               | 67.67 ± 7.42* | 64.87 ± 8.98* |
| 6MWD (meters)                  | 336.73 ± 65.92* | 317.93 ± 78.54* |
| SGRQ total score               | 60.02 ± 17.34* | 63.50 ± 16.43* |

*Mean (±SD), p < 0.05; Group A: experimental; Group B: control.

Subject characteristics in both groups are shown in Table 1. At the end of the programme, there were significant changes in 6MWD, HRQOL, and FEV1 from baseline to the 3rd week (Table 2).

At the end of 3 weeks, the mean percentage change in 6MWD in the experimental group was 20.56 (5.14) and in the control group was 4.60 (2.03). The mean percentage of the total SGRQ score was 37.39 (10.99) and 8.21 (6.96) for the experimental and control groups, respectively (Figures 1 and 2). The mean difference between the two groups was statistically significant (p < 0.05). The mean change in 6MWD & SGRQ values within both the groups at the 3rd and 6th week was statistically significant.

Discussion

The results have shown that a short-term PRP was able to increase exercise capacity, pulmonary function and quality of life in COPD patients. Scientific evidence was established regarding the benefits of PRPs, as reported by AACVPR practice guidelines for pulmonary rehabilitation. These benefits include a reduction in dyspnoea, improved quality of life, and a decrease in health care use. The present study has shown progress in exercise capacity as measured by percentage change in 6MWD after PRP at the end of 3 weeks (20.56 ± 5.14) and at the end of 6 weeks (27.54 ± 6.93) in the experimental group. These results are in line with Miyahara et al. (2000) who reported an increase in 6MWD as a measure of functional exercise capacity after 3 weeks of PRP in COPD patients. The increase in exercise capacity or tolerance may be ascribed to improved aerobic capacity of muscle, increased motivation, and desensitization to the sensation of dyspnoea. Improved aerobic capacity of muscle has been shown through an increase in the ability of the muscle to extract oxygen more thoroughly from circulating blood, a decrease in heart rate during exercise, a reduction in exercise-induced oxidative stress, exercise-induced lactic acidosis, and enhanced skeletal muscle oxidative capacity in patients with COPD.

Dyspnoea upon exertion was reduced, as reflected in the scores of the QOL questionnaire. Since dyspnoea has a major impact on health status, patients’ improved quality of life can be suggestive of a decrease in symptoms. Reduction in dyspnoea, or shortness of breath, can be attributable to reduced ventilatory demand, reduced independence to ventilatory muscle action, improved ventilatory muscle performance.
characteristics and psychological factors. This study has shown significant improvements in quality of life as measured by a mean percentage change in SGRQ and a disease specific questionnaire at the end of 3 weeks (37.39 ± 10.99) and at the end of 6 weeks (62.51 ± 11.49) compared to baseline (60.06 ± 17.34) in the experimental group. A change of four units on the SGRQ is considered a reliable, noticeable difference. Reduction in dyspnoea, and other symptoms, efficient breathing patterns, and improved ability to carry out daily activities could be reasons for the improvements in quality of life. Knowledge of the disease process, a need for and benefits of medication and exercises, work simplification and energy conservation techniques might be responsible for patients’ decreased fear of breathlessness and better control over their disease. Patients who were on their regular medical therapy experienced a decrease in symptoms as measured by better performance in their daily activities and greater independence in their abilities. A home exercise programme, which included walking and upper limb exercises, may also have contributed to an increase in exercise tolerance to some extent, which ultimately led to a positive impact on patients’ quality of life, as suggested by a mean percentage change in the total SGRQ score in the control group at the end of 3 weeks (8.21 ± 6.96) and at the end of 6 weeks (13.15 ± 8.42) compared to baseline (63.05 ± 16.43).

Benefits of PRP include improved exercise capacity and quality of life, irrespective of change in pulmonary function. In contrast, this study has shown significant changes in FEV1 after the exercise programme at the end of 3 weeks (p < 0.05) and at the end of 6 weeks (p < 0.05) in the experimental group. This improvement may be due to improved bronchodilator use or respiratory muscle strength/conditioning.

Apart from an increase in exercise capacity and quality of life, PRP also enhanced patients’ knowledge about their

| Variable | 6MWD  | SGRQ  | FEV1  |
|----------|-------|-------|-------|
|          | A     | B     | A     | B     |
| Baseline | 336.73* (65.92) | 317.93* (78.54) | 60.02* (17.34) | 63.50* (16.43) | 47.27* (11.07) | 45.87* (8.72) |
| 3 weeks  | 403.13* (64.34) | 331.73* (79.38) | 36.90* (10.69) | 57.77* (13.88) | 68.13* (7.83)  | 64.53* (9.12)  |
| 6 weeks  | 425.93* (65.85) | 337.60* (80.54) | 21.99* (8.26)  | 54.42* (12.49) | 50.20* (12.19) | 65.00* (8.41)  |

*Mean (±SD), p < 0.05; A: experimental; B: control; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; 6MWD: 6 minute walk distance; SGRQ: St. George’s Respiratory Questionnaire.
An exercise programme for the muscles of ambulation is a part of virtually every programme of pulmonary rehabilitation. In this study, a variety of exercises were incorporated, including treadmill and cycle ergometry, an endurance training programme, upper limb exercises, and thoracic mobility exercises that made this programme more realistic and functionally relevant to daily activities. Exercise training included arm and leg training, which improves exercise tolerance, and training effects were specific to the muscle group trained without any crossover benefits. In this study, the experimental group had undergone a lower limb endurance exercise programme as well as thoracic mobility and upper limb exercises apart from the home exercise programme, while the control group was taught only about the home exercise programme; unstructured patient education and counselling were done in both groups. As both groups were on medication in addition to the exercise programmes, both groups showed significant improvement in exercise capacity, quality of life and pulmonary function, which is in line with numerous studies showing varied results based on different exercise training programmes, duration and frequency of training and outcome measures used.

Recommendations and conclusion

Limitations of the study included the small size of the study sample and the availability of male patients. Future research is required to formulate more efficient strategies for rehabilitation that address the individual needs of the patients and to examine the benefits of the individual component of the multidisciplinary rehabilitation programmes.

In conclusion, a short-term pulmonary rehabilitation programme has improved exercise capacity, pulmonary function and quality of life in COPD patients. The improvement in exercise capacity is present, irrespective of the severity of airflow limitation.

Conflicts of interest

The authors have no conflicts of interest to declare.

Authors’ contributions

BAN, M.P.Th — Conception and design of the work. AA, PhD — Drafting the article with clarifications. AHA, PhD — Data collection, analysis and interpretation. TA, MS — Accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved. GG, M.P.Th — Drafting the work or revising it critically for important intellectual content. MF, MD — Critical vision of the article.

References

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3(11): e442. http://dx.doi.org/10.1371/journal.pmed.0030442.
2. Lopez D, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27: 397–412.
3. Jindal Surinder K. Emergence of chronic obstructive pulmonary disease as an epidemic in India. Indian J Med Res Dec 2006.
4. Singh Virendra, Khandelwal Dinesh Chaudh, Khandelwal Rakesh, Abusaria Suendra. Pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci 2003; 45: 13–17.
5. GOLD Executive Committee 2007. Revised 2007. www.goldcopd.com.
6. Nici, Donner C, Wouters Emiel, Zuwailack R, Ambrosino N. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006; 173: 1390–1413.
7. O’Shea Simone D, Taylor Nicholas F, Paratz Jennifer. Peripheral muscle strength training in COPD. A Syst Rev 2004; 126: 903–914.
8. Birmann Michael J. Exercise in patients with chronic obstructive pulmonary disease. Pulmonaryrehabilitation in chronic respiratory insufficiency Thorax 1993; 48: 936–946.
9. Troosters Thierry, Casaburi Richard, Gosselink Rik, Decramer Marc. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 19–38.
10. Kochanek KD, Murphy SL, Xu J, Tejada-Vera B. Deaths: final data for 2014. Nat Vital Stat Rep 2016; 65(4): 1–121.
11. Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH. COPD surveillance—United States, 1999—2011. Chest 2013; 144(1): 284–305. http://dx.doi.org/10.1378/chest.13-0809.
12. Yawn B, Mannino D, Littlejohn T, et al. Prevalence of COPD among symptomatic patients in a primary care setting. Curr Med Res Opin 2009; 25(11): 2671–2677. http://dx.doi.org/10.1185/03007990903241350.
13. Price D, Crockett A, Arne M, et al. Spirometry in primary care case-identification, diagnosis and management of COPD. Prim Care Respir J 2009; 18(3): 216–223. http://dx.doi.org/10.4104/pcrj.2009.00055.
14. Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J Chron Obstruct Pulmon Dis 2011; 6: 573–581.
15. GOLD website. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd. Published 2016. Accessed April 2017. Rennard S, Thomasbow H, Crapu J, et al. Introducing the COPD Foundation guide for diagnosis and management of COPD, recommendations of the COPD foundation. COPD 2013; 10(3): 378–389. http://dx.doi.org/10.3109/15412555.2013.81309.
16. Zhang Q, Wang C, Ma Q. Modified Medical Research Council questionnaire and COPD assessment test are inconsistent. Eur Respir J 2013; 42: P2143.
17. Yawn BP, Wollan P, Rank M. Exacerbations in the pre- and postCOPD diagnosis periods. Pragmat Obs Res 2013; 4: 1–6. http://dx.doi.org/10.2147/por.s41778.
18. Siakas N. Preventing exacerbations of COPD—advice from hippocrates. N Engl J Med 2011; 365: 753–754. http://dx.doi.org/10.1056/NEJMra1106979.
19. Postma DS, Bate KF. The asthma—COPD overlap syndrome. N Engl J Med 2015; 373: 1241–1249. http://dx.doi.org/10.1056/NEJMa1411863.
20. Mapel D. Insights into COPD comorbidities from the OLIN study and other large databases. COPD 2011; 8(6): 397–399. http://dx.doi.org/10.3109/15412555.2011.636555.
21. Lowry KP, Gazelle GS, Gilmore ME, et al. Personalizing annual lung cancer screening for patients with chronic obstructive
pulmonary disease: a decision analysis. Cancer 2015; 121(10): 1556–1562. http://dx.doi.org/10.1002/cncr.29225.

22. U.S. Preventive Services Task Force. Lung Cancer: Screening. Recommendation Summary. U.S. Preventive Services Task Force website. https://www.uspreventiveservicestaskforce.org/Page/Name/tools-and-resources-for-better-preventive-care Published December 2013. Accessed April 2017.

23. de-Torres JP, Wilson DO, Sanchez-Salcedo P, et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med 2015; 191(3): 285–291. http://dx.doi.org/10.1164/rccm.201407-1210OC.

24. Qaseem A, Wilt TJ, Weinberger SE, et al., for the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155(3): 179–191. http://dx.doi.org/10.7326/0003-4819-155-3-201108020-00006.

25. Regan EA, Lynch DA, Curran-Everett D, et al., for the COPD Genetic Epidemiology investigators. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern Med 2015; 175(9): 1539–1549. http://dx.doi.org/10.1001/jamainternmed.2015.2735.

26. Woodruff PG, Barr RG, Bleecker E. et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med 2016; 374(19): 1811–1821. http://dx.doi.org/10.1056/NEJMoa1505971.

27. Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta2-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax 2016; 71(1): 15–25. http://dx.doi.org/10.1136/thoraxjnl-2014-206732.

28. Roberts MH, Mapel D, Harty A, Von Worley A, Thomson H. Chronic pain and pain medication use in chronic obstructive pulmonary disease. A cross-sectional study. Ann Am Thor Soc 2013; 10(4): 290–298. http://dx.doi.org/10.1513/AnnalsATS.201303-040OC.

How to cite this article: Naseer BA, Al-Shenqiti AM, Ali AH, Al-Jeraisi TM, Gunjan GG, Awaaldalah MF. Effect of a short term pulmonary rehabilitation programme on exercise capacity, pulmonary function and health related quality of life in patients with COPD. J Taibah Univ Med Sc 2017;12(6):471–476.